HealthAI imageNAVER D2SF Invests in AI-Driven Precision Medicine Firm ImpriMed
NAVER D2SF has invested in ImpriMed, a Silicon Valley-based company developing AI-driven precision medicine solutions for personalized cancer treatment. ImpriMed's $10 million Series A2 bridge round supports U.S. commercialization and Asian expansion. Their xCellSense® platform integrates ex vivo cancer cell testing with genomic and clinical data. The company targets FDA clearance by early 2027 and collaborates with major hospitals in South Korea and the U.S.
Pr Newswire Apac··Seoul


